| Epigenetic stem cell signature in cancer M Widschwendter, H Fiegl, D Egle, E Mueller-Holzner, G Spizzo, C Marth, ... Nature genetics 39 (2), 157-158, 2007 | 1247 | 2007 |
| Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial M Gnant, G Pfeiler, PC Dubsky, M Hubalek, R Greil, R Jakesz, V Wette, ... The Lancet 386 (9992), 433-443, 2015 | 622 | 2015 |
| Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a … A Di Leo, S Johnston, KS Lee, E Ciruelos, PE Lønning, W Janni, ... The Lancet Oncology 19 (1), 87-100, 2018 | 410 | 2018 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 286 | 2022 |
| Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study EL Mayer, AC Dueck, M Martin, G Rubovszky, HJ Burstein, ... The lancet oncology 22 (2), 212-222, 2021 | 268 | 2021 |
| Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo … M Gnant, G Pfeiler, GG Steger, D Egle, R Greil, F Fitzal, V Wette, M Balic, ... The Lancet Oncology 20 (3), 339-351, 2019 | 241 | 2019 |
| Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP … L Gianni, CS Huang, D Egle, B Bermejo, C Zamagni, M Thill, A Anton, ... Annals of Oncology 33 (5), 534-543, 2022 | 231 | 2022 |
| Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer … L Gianni, CS Huang, D Egle, B Bermejo, C Zamagni, M Thill, A Anton, ... Cancer research 80 (4_Supplement), GS3-04-GS3-04, 2020 | 198 | 2020 |
| Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer M Gnant, F Fitzal, G Rinnerthaler, GG Steger, S Greil-Ressler, M Balic, ... New England Journal of Medicine 385 (5), 395-405, 2021 | 140 | 2021 |
| Spatial predictors of immunotherapy response in triple-negative breast cancer XQ Wang, E Danenberg, CS Huang, D Egle, M Callari, B Bermejo, ... Nature 621 (7980), 868-876, 2023 | 138 | 2023 |
| HE4 is an independent prognostic marker in endometrial cancer patients I Mutz-Dehbalaie, D Egle, S Fessler, M Hubalek, H Fiegl, C Marth, ... Gynecologic oncology 126 (2), 186-191, 2012 | 119 | 2012 |
| Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry SP Gampenrieder, G Rinnerthaler, C Tinchon, A Petzer, M Balic, S Heibl, ... Breast Cancer Research 23 (1), 112, 2021 | 111 | 2021 |
| Toll‐like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors R Berger, H Fiegl, G Goebel, P Obexer, M Ausserlechner, W Doppler, ... Cancer science 101 (4), 1059-1066, 2010 | 106 | 2010 |
| Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized … T Foukakis, G Von Minckwitz, NO Bengtsson, Y Brandberg, B Wallberg, ... Jama 316 (18), 1888-1896, 2016 | 103 | 2016 |
| A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NEO-ORB) IA Mayer, A Prat, D Egle, S Blau, JAP Fidalgo, M Gnant, PA Fasching, ... Clinical Cancer Research 25 (10), 2975-2987, 2019 | 96 | 2019 |
| Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs) A Oberguggenberger, M Hubalek, M Sztankay, V Meraner, B Beer, ... Breast cancer research and treatment 128, 553-561, 2011 | 96 | 2011 |
| Use of underarm cosmetic products in relation to risk of breast cancer: a case-control study C Linhart, H Talasz, EM Morandi, C Exley, HH Lindner, S Taucher, D Egle, ... EBioMedicine 21, 79-85, 2017 | 81 | 2017 |
| Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients G Goebel, R Berger, AM Strasak, D Egle, E Müller-Holzner, S Schmidt, ... British journal of cancer 106 (1), 189-198, 2012 | 78 | 2012 |
| Abstract S2-02: the impact of adjuvant denosumab on disease-free survival: results from 3,425 postmenopausal patients of the ABCSG-18 trial M Gnant, G Pfeiler, PC Dubsky, M Hubalek, R Greil, R Jakesz, V Wette, ... Cancer Research 76 (4_Supplement), S2-02-S2-02, 2016 | 77 | 2016 |
| LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial G Bianchini, CS Huang, D Egle, B Bermejo, C Zamagni, M Thill, A Anton, ... Annals of Oncology 31, S1145-S1146, 2020 | 66 | 2020 |
